Compugen Ltd. Stock TEL AVIV STOCK EXCHANGE
Equities
IL0010852080
Biotechnology & Medical Research
Sales 2024 * | 37.9M 14.43B | Sales 2025 * | 35.29M 13.43B | Capitalization | 170M 64.76B |
---|---|---|---|---|---|
Net income 2024 * | -13M -4.95B | Net income 2025 * | -29M -11.04B | EV / Sales 2024 * | 4.49 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.82 x |
P/E ratio 2024 * |
-14.6
x | P/E ratio 2025 * |
-7.04
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.62% |
Latest transcript on Compugen Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Anat Cohen-Dayag
CEO | Chief Executive Officer | 57 | 01-12-31 |
Alberto Sessa
DFI | Director of Finance/CFO | 61 | 22-10-31 |
Eran Ophir
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 66 | 17-10-01 |
Sanford Zweifach
BRD | Director/Board Member | 68 | 18-06-10 |
Gilead Halevy
BRD | Director/Board Member | 57 | 18-06-10 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |